Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.09.001
Abstract: Introduction: Immune checkpoint inhibitors (ICIs) are standard therapies in advanced NSCLC. Although genotype‐directed tyrosine kinase inhibitors represent the standard of care for subsets of oncogene‐driven NSCLC, patients may receive ICIs during their disease course. The… read more here.
Keywords: crizotinib; transaminase level; hepatotoxicity; therapy ... See more keywords